Fredrik Liedberg, Truls Gårdmark, Oskar Hagberg, Firas Aljabery, Viveka Ströck, Abolfazl Hosseini, Per-Uno Malmström, Karin Söderkvist, Anders Ullén, Tomas Jerlström, Staffan Jahnson, Lars Holmberg, Christel Häggström
{"title":"Treatment Related to Urinary Tract Infections Is Associated with Delayed Diagnosis of Urinary Bladder Cancer: A Nationwide Population-based Study.","authors":"Fredrik Liedberg, Truls Gårdmark, Oskar Hagberg, Firas Aljabery, Viveka Ströck, Abolfazl Hosseini, Per-Uno Malmström, Karin Söderkvist, Anders Ullén, Tomas Jerlström, Staffan Jahnson, Lars Holmberg, Christel Häggström","doi":"10.1016/j.euo.2024.07.008","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>It has been suggested that urinary tract infections (UTIs) are associated with delayed diagnosis of bladder cancer (BC). Our aim was to investigate prediagnostic treatments related to UTI and the relation to BC diagnostic delay, reflected by advanced disease at diagnosis.</p><p><strong>Methods: </strong>We used data from the BladderBaSe 2.0 with data of treatments related to UTI up to 3 yr before BC diagnosis (2008-2019) for BC patients in comparison to a matched reference population. We investigated the association between UTI treatments and more advanced disease at diagnosis in the BC cohort. We used generalized ordered logistic regression to calculate odds ratios (ORs) for more advanced disease as an ordered outcome: non-muscle-invasive BC (NMIBC), muscle-invasive BC (MIBC), and metastatic BC (MBC).</p><p><strong>Key findings and limitations: </strong>The study population included 29 921 BC patients and 149 467 matched reference subjects. The proportions of individuals receiving UTI treatment were higher in the patient groups than in the corresponding reference groups, with the greatest differences observed for the MIBC and MBC subgroups. The OR for the risk of more advanced disease (MIBC or MBC) with at least one UTI treatment versus none was 1.28 (95% confidence interval [CI] 1.19-1.37) for men and 1.42 (95 % CI 1.27-1.58) for women. The association to risk of more advanced disease increased with the number of UTI treatments for both sexes.</p><p><strong>Conclusions and clinical implications: </strong>Further studies on the effects of treatments related to UTI in combination with other factors are needed to identify reasons for possible delays in the BC diagnostic pathway.</p><p><strong>Patient summary: </strong>We found that for patients with bladder cancer, previous antibiotic treatment for a urinary tract infection was linked to more advanced disease at diagnosis. Further studies are needed to identify reasons for possible delays in the diagnosis of bladder cancer.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.3000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2024.07.008","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objective: It has been suggested that urinary tract infections (UTIs) are associated with delayed diagnosis of bladder cancer (BC). Our aim was to investigate prediagnostic treatments related to UTI and the relation to BC diagnostic delay, reflected by advanced disease at diagnosis.
Methods: We used data from the BladderBaSe 2.0 with data of treatments related to UTI up to 3 yr before BC diagnosis (2008-2019) for BC patients in comparison to a matched reference population. We investigated the association between UTI treatments and more advanced disease at diagnosis in the BC cohort. We used generalized ordered logistic regression to calculate odds ratios (ORs) for more advanced disease as an ordered outcome: non-muscle-invasive BC (NMIBC), muscle-invasive BC (MIBC), and metastatic BC (MBC).
Key findings and limitations: The study population included 29 921 BC patients and 149 467 matched reference subjects. The proportions of individuals receiving UTI treatment were higher in the patient groups than in the corresponding reference groups, with the greatest differences observed for the MIBC and MBC subgroups. The OR for the risk of more advanced disease (MIBC or MBC) with at least one UTI treatment versus none was 1.28 (95% confidence interval [CI] 1.19-1.37) for men and 1.42 (95 % CI 1.27-1.58) for women. The association to risk of more advanced disease increased with the number of UTI treatments for both sexes.
Conclusions and clinical implications: Further studies on the effects of treatments related to UTI in combination with other factors are needed to identify reasons for possible delays in the BC diagnostic pathway.
Patient summary: We found that for patients with bladder cancer, previous antibiotic treatment for a urinary tract infection was linked to more advanced disease at diagnosis. Further studies are needed to identify reasons for possible delays in the diagnosis of bladder cancer.
背景和目的:有研究表明,尿路感染(UTI)与膀胱癌(BC)的延迟诊断有关。我们的目的是调查与UTI相关的诊断前治疗以及UTI与膀胱癌诊断延迟的关系,诊断时的晚期疾病反映了这一点:我们使用了来自 BladderBaSe 2.0 的数据,其中包括 BC 患者在 BC 诊断前 3 年(2008-2019 年)接受的 UTI 相关治疗的数据,并与匹配的参照人群进行了比较。我们研究了 BC 队列中UTI 治疗与确诊时疾病晚期之间的关联。我们使用广义有序逻辑回归计算了作为有序结果的晚期疾病的几率比(ORs):非肌浸润性BC(NMIBC)、肌浸润性BC(MIBC)和转移性BC(MBC):研究对象包括 29 921 名 BC 患者和 149 467 名匹配参照对象。患者组中接受UTI治疗的比例高于相应的参照组,其中MIBC和MBC亚组的差异最大。至少接受过一次UTI治疗与未接受UTI治疗相比,男性晚期疾病(MIBC或MBC)风险的OR值为1.28(95% 置信区间[CI] 1.19-1.37),女性为1.42(95 % CI 1.27-1.58)。男女患者罹患晚期疾病的风险随着UTI治疗次数的增加而增加:患者小结:我们发现,对于膀胱癌患者而言,既往接受过尿路感染抗生素治疗与确诊时病情更晚期有关。需要进一步研究以确定膀胱癌诊断可能出现延误的原因。
期刊介绍:
Journal Name: European Urology Oncology
Affiliation: Official Journal of the European Association of Urology
Focus:
First official publication of the EAU fully devoted to the study of genitourinary malignancies
Aims to deliver high-quality research
Content:
Includes original articles, opinion piece editorials, and invited reviews
Covers clinical, basic, and translational research
Publication Frequency: Six times a year in electronic format